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A B S T R A C T   
An in silico trial simulates a disease and its corresponding therapies on a cohort of virtual patients to support the 
development and evaluation of medical devices, drugs, and treatment. In silico trials have the potential to refine, 
reduce cost, and partially replace current in vivo studies, namely clinical trials and animal testing. We present the 
design and implementation of an in silico trial for treatment of acute ischemic stroke. We propose an event-based 
modelling approach for the simulation of a disease and injury, where changes to the state of the system (the 
events) are assumed to be instantaneous. Using this approach we are able to combine a diverse set of models, 
spanning multiple time scales, to model acute ischemic stroke, treatment, and resulting brain tissue injury. The in 
silico trial is designed to be modular to aid development and reproducibility. It provides a comprehensive 
framework for application to any potential in silico trial. A statistical population model is used to generate cohorts 
of virtual patients. Patient functional outcomes are also predicted with a statistical model, using treatment and 
injury results and the patient’s clinical parameters. We demonstrate the functionality of the event-based 
modelling approach and trial framework by running proof of concept in silico trials. The proof of concept tri-
als simulate the same cohort of patients twice: once with successful treatment (successful recanalisation) and 
once with unsuccessful treatment (unsuccessful treatment). Ways to overcome some of the challenges and dif-
ficulties in setting up such an in silico trial are discussed, such as validation and computational limitations.   
1. Introduction 
Research and development of novel medical devices, drugs, and 
treatments is expensive—the average cost to bring a new drug to market 
has been estimated at 1–2.5 billion US dollars [1,2]. Clinical trial failure 
contributes to the increasing costs and can result in abandoned products, 
often without a clear understanding of the reason for the failure [3,4]. 
Several difficulties in traditional clinical trials relate to their dependence 
on large cohorts of participants to achieve the required statistical power 
for regulatory approval [5]. Clinical trials for higher prevalence dis-
eases, with high participation, often only capture the average popula-
tion, thereby missing important effects occurring in only a small 
percentage of the population. This can lead to unforeseen side-effects 
when the product is brought to market. In contrast, clinical trials for 
low prevalence diseases can struggle to recruit the requisite number of 
patients, making development of treatments for these diseases 
economically infeasible. 
To help counteract difficulties surrounding clinical trials, researchers 
are exploring computational biomedicine as a way to augment in vitro 
and in vivo trials. These in silico experiments are facilitated by de-
velopments in computational modelling in biomedicine [6–11]. The 
so-called in silico trial (IST) [12] can specifically consider cohorts of 
virtual patients representing highly specific population subsets. Using 
results from ISTs, a clinical trial can potentially reduce the number of 
required patients and be more targeted in patient selection. This reduces 
development time, and hence costs, for clinical trials, in particular those 
considering rare diseases. 
ISTs are closely related to computational biomedicine and person-
alised medicine [13]. Personalised medicine aims to predict the outcome 
of a patient-specific treatment at an individual level, using 
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patient-specific characteristics or a virtual representation of the real 
patient. In contrast, ISTs predict outcome at the population level by 
modelling disease and treatment over a cohort of virtual patients that 
provide a statistical representation of the population of interest. In this 
context, the virtual patient represents a patient using a set of parameters 
used for the computational models and simulations, and prognostic 
factors for patient outcome. The goal is to predict the efficacy and effi-
ciency of a treatment, drug, or device; similar to traditional in vitro and 
in vivo clinical trials. A summary of the current state of computational 
modelling in medical product development can be found in the Avicenna 
Roadmap [12,14]. This roadmap provides a clear vision towards in silico 
methods for development of medical products, together with an in-depth 
discussion on the benefits and obstacles for ISTs. 
There are several technical, modelling, and legal challenges to suc-
cessfully developing ISTs. One such challenge of patient-specific 
computational modelling is the requirement for patient-specific pa-
rameters. These are often derived from patient data such as clinical 
measurements and images. Sharing patient data is difficult due to pri-
vacy regulations [14–16]. Even without this restriction, outcome pre-
dictions would only be valid for the cohort of patients for whom all the 
required data was measured. Capturing an entire cohort of patients 
therefore requires a more systematic approach such as a statistical 
model of the population. A statistical model enables the combination of 
commonly measured characteristics, e.g. blood pressure and age, with 
rarely collected characteristics, such as clot histological composition, 
structure, and length in the case of acute ischemic stroke. 
Acute ischemic stroke (AIS) is the disease of interest for this paper. 
AIS is an occlusion of the arteries supplying blood to the brain and has 
been estimated to cause 2.7 million deaths globally and account for 51.9 
million disability-adjusted life-years [17]. The current standard of care 
in the EU for treatment of AIS is intravenous thrombolysis, usually 
within 4.5 h of stroke onset, followed by intra-arterial thrombectomy 
(for large vessel occlusions), usually within 6 h of stroke onset [18,19]. 
Though recent trials have shown extending this time window may 
improve patient outcomes in a selective group of patients with AIS due 
to large vessel occlusions based on perfusion imaging criteria [20,21]. 
Development of new thrombectomy devices and thrombolysis drugs 
require further trials, creating potential use cases for an IST. Other use 
cases include evaluating new indications for reperfusion therapies (e.g. 
an in silico MR CLEAN Late trial [22]) or different combinations of 
reperfusion strategies (e.g. an in silico MR CLEAN NO-IV [23]). 
We are interested in developing an IST for reperfusion therapies in 
patients with AIS. We only consider patients with ischemic stroke due to 
a large vessel occlusion who are eligible for reperfusion treatment using 
thrombectomy, as in the MR CLEAN Trial and Registry [24,25]. Trial 
results are also limited to the current standard of care: treatment within 
6.5 h, as the MR CLEAN Registry and MR CLEAN trial only consider 
patients treated within 6.5 and 6 h respectively [24,25]. The IST 
framework presented here has been developed as part of the INSIST 
project—a collaborative effort of academic and industrial partners to 
develop ISTs for the treatment of AIS [26–28]. The work within INSIST 
includes development of a statistical model for generating a virtual 
population; various computational models of brain injury and stroke 
treatment predicting infarct (dead tissue) volume; and a statistical 
clinical outcome model. 
We propose an event-based modelling approach for the simulation of 
brain injury and stroke treatment. In this model we assume that changes 
to the system, such as the occlusion event and reperfusion after treat-
ment, are instantaneous on the simulated time scale: typically hours 
between occlusion and treatment, with an additional follow up at 24 h. 
To capture the physiology of all events we require detailed models 
which are typically hard to set up, and have high system requirements 
and long execution times. Due to the event-based approach, the inter-
action of multiple detailed models is simplified: each model updates the 
system’s state sequentially, generally in a predetermined order. This 
provides flexibility in the infrastructure used to evaluate the individual 
models, e.g. compute systems ranging from small workstations to large- 
scale cloud computing or High Performance Computing (HPC) facilities 
can be used. Alternatively, computationally expensive models can be 
replaced easily by more efficient surrogate models by changing the 
model definitions within the event-driven in silico trial. 
In this paper we present our event-based modelling approach and the 
IST framework, developed based on the strategy described in the INSIST 
white paper [28]. This is one of the first comprehensive frameworks 
incorporating all aspects required to run an IST using multiple models, 
and the first we are aware of that has been applied to acute ischemic 
stroke. We analyse the use of an event-based modelling approach to 
combine models of blood flow, tissue perfusion, thrombolysis, throm-
bectomy, and tissue death and provide an accompanying open source 
application to support the generation, simulation, and analysis of 
event-based ISTs. Results are compared for two proof of concept trials, 
run on the same virtual population cohort. In one trial all patients have 
successful recanalisation (best case), and in the other all patients have 
unsuccessful recanalisation (worst case). Further challenges in setting 
up an IST trial are also discussed. 
2. Methods 
2.1. INSIST framework 
For the IST we implement the 4 module approach proposed in the 
INSIST white paper [28]. The clinical trial is split into its basic compo-
nents, which we call modules in the INSIST framework: Module I) 
generate a population of virtual patients; Module II) model the dis-
ease/condition and treatment; Module III) estimate patient outcome; 
and Module IV) determine the trial outcome. The final outputs of 
Module II are infarct volume and procedural (treatment) outcomes, 
which is then passed to Module III along with the patient’s clinical data 
from Module I. Module III estimates clinical outcomes for each patient, 
which are then collated across the population in Module IV. These 
modules, and the workflow, are shown in Fig. 1. 
2.1.1. Module I: virtual population 
The first module—the virtual population generation—generates a 
cohort of virtual patients for the IST. INSIST uses a statistical model to 
generate these patients. An alternative would be to build a population 
using samples of real patient data. Generating a cohort of virtual patients 
using a statistical population model is a way to overcome (some of) the 
privacy issues surrounding the use of real patient data. A secondary 
benefit is the potential to sample an arbitrary number of patients at the 
extremes of distributions, which have limited representation in tradi-
tional clinical trials, to assist in the design of clinical trials. However, 
significant sampling at the extremes of the distribution is contingent on 
proving the credibility of the virtual population model at the extremes. 
In the context of INSIST, a virtual patient consists of a set of pa-
rameters, such as clinical and thrombus parameters, and other relevant 
variables, including vessel geometries, required for the simulation of 
AIS, treatment, and outcome estimation. The statistical model to 
generate the virtual population’s clinical data (age, blood pressure, etc.) 
is a vine copula model [29] developed in R using rvinecopulib [30]. Data 
from 3180 ischemic stroke patients who underwent thrombectomy (MR 
CLEAN Registry [25]) was used to fit the model. Parameters were 
selected based on required inputs for Module II, but also on their 
prognostic value [31]. Imaging and thrombus characteristics are linked 
to clinical data using linear regression models for a subset of patients 
[32–34]. A list of the parameters, and the number of observations used, 
is given in Table 1. Users can also specify inclusion and exclusion 
criteria, limited by the included model parameters, to generate 
sub-populations of virtual patients. 
2.1.2. Module II: modelling stroke and treatment 
The second module simulates AIS, treatment, and brain tissue injury. 
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The outcome of interest from this module is the infarct volume and 
procedural outcomes. In order to simulate the tissue injury, it is neces-
sary to know the change between the pre-stroke, stroke (occluded), and 
post-treatment state of the brain. As such, models may be required to be 
run for several events, as shown in Table 2. Given the characteristic time 
periods occurring between stroke and treatment, we use an event-based 
modelling approach in which changes between states are assumed to be 
instantaneous compared to the timescale of the simulated time span 
(onset of stroke to final outcome). This is described in detail in section 
2.2. 
There will be five interacting physics based models in Module II. The 
five models are:  
1. Arterial blood flow models the blood flow from the heart to the pial 
surface. We use a 1D pulsatile model covering vessels with diameters 
greater than 0.1 mm. The state of blood flow in the vessels of the 
vasculature is mapped to the pial surface of the brain mesh and 
provides the boundary condition for the perfusion model (below). 
The governing equations for the model are given in Appendix A.1, 
and details on this model, and its one way coupling to the perfusion 
model, can be found in Ref. [35].  
2. Perfusion models the blood perfusion within the brain. This is a 3D 
steady state finite element model describing blood flow in the 
microcirculation using three porous compartments: arteriole, capil-
lary, and venule. Governing equations for the model are given in 
Appendix A.2. and a detailed description of the model can be found 
in Ref. [36]. The output steady state perfusion distribution (in both 
grey and white matter) provides the input to the tissue health model.  
3. Tissue health models reversible and irreversible tissue damage as a 
result of blood flow shortage, and consequently hypoxia [37]. This is 
done based on the perfusion simulation results. Further details are 
given in Appendix A.3.  
4. Thrombolysis models dissolution of the thrombus after drug, typically 
tPA (tissue plasminogen activator), administration [38,39]. This 
could be a lattice boltzmann model of tPA transport to a thrombus, 
composed of heterogeneous fibrin and blood cells, or an empirical 
model depending on the level of detail required.  
5. Thrombectomy models the thrombectomy procedure. A detailed 
model of thrombectomy using finite element analysis was developed 
[33,40], but the trial will use a surrogate kriging model fitted on a 
sample of full model simulations for computational reasons. 
For the results shown in this paper, we only use the arterial blood 
flow, perfusion, and tissue death models. The run time per virtual pa-
tient, in this paper, is approximately 16 min. This includes generation of 
the virtual cohort, distribution and running all patient simulations, and 
analysis of outcome. Of these 16 min, 200 s are spent in the blood flow 
model, 350 s within the perfusion models (totals for the two events), and 
400 s in the tissue health model. Future work will incorporate the 
thrombolysis and thrombectomy models into the pipeline, as well as 
ongoing improvements to the models already included here. 
2.1.3. Module III: estimating patient outcome 
The third module of INSIST determines the neurological deficit and 
functional outcome outcome for each patient. The two clinical outcome 
measures of interest are NIHSS (National Institutes of Health Stroke 
Scale) and mRS (modified Rankin Scale). NIHSS categorises stroke 
impairment from 0: no symptoms to 42: severe stroke. Similarly, mRS 
categorises functional outcome between 0: no symptoms and 6: death. 
Procedural outcomes and infarct volume from Module II and the 
patient’s clinical parameters from Module I are used as predictors to 
estimate clinical outcome. Data on follow-up infarct volumes from the 
MR CLEAN trial were used to estimate the regression coefficient for 
predicting mRS and NIHSS after treatment [24]. The clinical parameters 
Fig. 1. A schematic view of the set-up of the INSIST framework, showing the flow between the various modules of the IST. Patient data is used to create the statistical 
population model that generates the virtual cohort. For each patient brain tissue damage after stroke and treatment are simulated. These simulation outcomes are 
used to predict the virtual patient’s clinical outcome. Finally, the results of all virtual patients are combined and analysed, providing a clinical report of the 
IST’s outcome. 
Table 1 
The parameters from the virtual population, split into those found to be signif-
icant in determining patient outcome, and those used in the models in Module II. 
Imaging and thrombus data observation count varied between variables, and is 
indicated in the parenthesis after each parameters. M1: M1 segment of middle 
cerebral artery; ICA: internal carotid artery.   
Clinical data Imaging and thrombus data 
Number of 
observations 
3180 Varies (counts for each 




age, sex, occlusion location, 
diabetes mellitus, NIHSS at 
baseline, time from onset to ER, 
time from ER to thrombectomy  
Module II 
parameters 
occlusion location, time from 
onset to ER, time from ER to 
thrombectomy, systolic blood 
pressure, diastolic blood 
pressure 
Clot percent fibrin (332), clot 
length (399), ICA radius 
(122), M1 radius (122), ICA 
length (122), ICA tortuosity 
(122)  
Table 2 
Models run for each event (pre-stroke, stroke, treatment, and final outcome), 
and the order of execution. In the final outcome event, the tissue death model 
uses the change in states and timings of each of the events to integrate the model 
from the stroke onset to the follow up time.   
Pre-stroke Stroke Treatment Final outcome 
Thrombolysis   5  
Thrombectomy   6  
Arterial blood flow 1 3 7  
Perfusion 2 4 8  
Tissue death    9  
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from the virtual population model determined significant for patient 
outcome and used in these models are listed in Table 1 (prognostic 
parameters). 
The model for NIHSS is a linear regression model. The model for mRS 
is an ordinal logistic regression model, similar to the model used in 
Ref. [31]. This mRS model provides the probability of being each mRS 
category for each patient. For the results in this paper, we randomly 
assign an mRS category using the distribution of each patient. 
2.1.4. Module IV: reporting trial outcome 
The final module collates the outcomes from all the patients and 
presents population summaries and statistics in an automatically 
generated HTML report. The report presents the summary statistics and 
distribution plots for both the generated clinical parameters from 
Module I and the determined outcomes of interest: mRS, NIHSS, infarct 
volume, and procedural outcomes from Modules II and III. The module 
also returns the notebook (RMarkdown [41]) file used to generate the 
report. This allows users to easily modify the report if further informa-
tion or plots are required. 
2.2. Event-based modelling 
We use an event-based simulation approach to combine the models 
in Module II and predict tissue injury. The timescale of interest for this 
model encompasses the period from stroke onset to the end of treatment: 
on the order of 0–6 h, plus follow up time: on the order of 24 h. 
Consequently, we assume major changes to the state of the system, 
which we call events (such as stroke onset or the effect of treatment), can 
be modelled as instantaneous changes in the system. The justification of 
this assumption for each of the events is discussed in detail below. Using 
this approach, Module II becomes a series of events for which the rele-
vant models are run in order to update the system to its new steady state, 
as shown in Fig. 2. In this framework, the term event encompasses both 
the trigger event, such as occlusion of an intracranial vessel, and the 
resulting change in the state of the system: the blood flow and perfusion. 
The timing of these events is determined per patient in Module I. 
As seen in Fig. 2, though we model the system as a series of events it 
is technically a hybrid system as tissue death occurs throughout the 
simulated time period, continuously increasing the size of the infarct 
region. In order to incorporate this within the system, we integrate the 
time-driven tissue death model in a single event at the end, using in-
formation about the time periods between each event and resulting 
perfusion states. 
In the AIS model, four events are required: pre-stroke, stroke onset, 
treatment, and final outcome (Fig. 2). Table 2 lists the models in the 
order of execution for each event. Each patient starts with a pre-stroke 
simulation. Arterial blood flow and tissue perfusion are computed 
before the onset of stroke. This model event has no timing associated 
with it—its purpose is to predict the original homeostatic state of the 
system. Stroke onset is simulated by placing a clot within one of the 
proximal intracranial arteries in the arterial blood flow model. Arterial 
blood flow and tissue perfusion are then updated accordingly. 
The relevant effect of the clot on blood flow and brain injury is the 
acute occlusion of the vessel. Modelling stroke onset as an instantaneous 
event is a good approximation as a clot is typically formed elsewhere in 
the body and travels through the vasculature until it occludes an artery 
[42–44]. Changes in blood flow through the large vessels of the vascu-
lature are fast—the waveforms of the cardiac cycle, e.g. pressure, vol-
ume flow rate, reach a new periodic cycle within a few seconds (based 
off model convergence). Consequently, given the hour time scale of the 
simulation, the error introduced by the instantaneous assumption would 
be negligible. 
Treatment usually starts within 6 h of stroke onset. In the event of a 
stroke, timing is critical: due to impaired blood flow, neurons are 
damaged and die fast due to their high energy demand [45]. Therefore, 
the reperfusion treatment needs to be started as soon as possible. In the 
trial thrombolysis followed by thrombectomy is simulated. After this 
arterial blood flow and tissue perfusion are updated. 
As can be seen in Fig. 2, the treatment for AIS can take place over a 
period of hours, which does not intuitively align with the instantaneous 
event assumption. However, we assume that the event of interest for 
reperfusion of the occluded territory is recanalisation of the vessel, 
either due to intravenous thrombolysis or endovascular thrombectomy. 
After recanalisation, the restoration of blood flow after removal of the 
clot is on the order of a few seconds, which, as in the case of stroke onset, 
is negligible compared to the time scale of the tissue injury simulation. 
In the case of thrombectomy, recanalisation occurs at the end of the 
procedure. The rest of the procedure, from groin puncture to the 
deployment of the balloon and stent, likely has little effect on the flow of 
blood through the obstructed vessel. In the case of thrombolysis, either 
the thrombolysis is successful and recanalisation occurs when the clot 
completely dissolves, or the new clot length is passed to the thrombec-
tomy model. Given thrombolysis is a time-dependent process, similar to 
the tissue death model, the model at the treatment event determines the 
change in clot length that would have occurred over the whole throm-
bolysis adminstration period. 
The assertion that recanalisation is the only event of interest for 
thrombolysis requires us to assume that blood flow through the clot does 
not change significantly during the thrombolysis period. Consequently, 
it is necessary to assume that thrombolysis does not affect clot properties 
enough to significantly change clot permeability, and the only signifi-
cant change is to clot length. This assumption is supported to a degree in 
a study by Rossi et al. [46] which found that thrombolysis (rtPA) reduces 
clot size but does not affect recanalisation outcome or number of passes 
in thrombectomy. If, however, this assumption is incorrect and throm-
bolysis does result in a significant change in blood flow through the clot 
(for a significant period of time), this will result in a, likely small, 
over-prediction of the infarct volume by the current model. If this error 
is found to be significant, multiple stepwise changes can easily be added 
to the proposed framework. 
Other situations that we don’t consider in the current setup are 
fragmentation and distal migration of the clot during treatment—clot 
migration has been found to occur in around 22% of cases from a sample 
of MR CLEAN Registry patients [47]—which would require additional 
models. Models of clot fragmentation are currently under development 
[48] and clot migration could be implemented in the future if it is 
determined to have a significant effect. 
2.3. Container implementation 
The event-based simulation approach in INSIST is enabled by des- 
ist [49]. This supporting application exploits containerised environ-
ments for the generation, simulation, and analysis of ISTs that can be 
Fig. 2. The DES implementation showing the events. Four events (changes in 
state of the blood flow and perfusion model) are modelled: pre-stroke, stroke, 
treatment, outcome. The treatment event accounts for the treatment success of 
both IVT and EVT at the end of the EVT. The change between states is assumed 
to be instantaneous compared to the simulated time span. IVT: intravenous 
thrombolysis. EVT: endovascular thrombectomy. Note: not to scale (e.g. follow 
up scan usually occurs 1 day after treatment). 
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implemented as discrete event simulations. This application captures the 
order of events, i.e. the evaluation order of the previously discussed 
models, as a directed, acyclic graph. Each node in this graph corresponds 
to a specific containerised environment, either using a Docker [50] or 
Singularity [51] container. Using containerised environments provides 
numerous advantages for ISTs such as collaboration independent of 
operating systems or hardware, straightforward reproducible simulation 
environments, and scaling towards large-scale cloud and HPC environ-
ments [52]. 
Once a cohort of virtual patients are generated, des-ist orches-
trates the evaluation of all necessary simulation steps and ensures the 
simulations are evaluated in the desired order for all patients present in 
the IST. For large cohorts, des-ist can evaluate the numerical simu-
lations in parallel on large-scale cloud or HPC compute environments. 
Various approaches are possible for parallelisation, such as running 
complete patient simulations per CPU or evaluating the all simulations 
of a single module in parallel. This flexibility allows to find the most 
efficient approaches considering the computational costs of individual 
events with respect to the available computational resources. Once all 
simulations are completed, regardless of their scheduling, the results are 
collected and analysed to provide an overview of the IST outcome. 
3. Results 
We run proof of concept trials with the INSIST trial framework. For 
this context, Module II consists of the arterial blood flow and tissue 
perfusion for three events: pre-stroke, stroke, and treatment, plus the 
tissue death model to determine patient infarct volume. Without 
detailed treatment models, solely binary treatment outcomes are 
considered representing complete reperfusion and no reperfusion. 
Consequently, the treatment model is hard coded to true and false 
respectively for two runs of the trial (on the same cohort). The two 
outcomes are equivalent to the best and worst case scenarios corre-
sponding to successful and failed treatments. 
3.1. Trial cohort 
The generation of the trial cohort is the first module of the INSIST 
framework. We base our cohort off the inclusion/exclusion criteria of 
the MR CLEAN trial. The MR CLEAN trial evaluated the efficacy of 
thrombectomy on patients with an intracranial large vessel occlusion by 
randomising patients between standard medical care and standard 
medical care plus endovascular thrombectomy [24,53]. The criteria 
used to define the population, from Ref. [53], are given in Table 4. Using 
this set of criteria we generate a cohort of 500 patients. Some charac-
teristics of the population are shown in Fig. 3 and summarised in 
Table 5. 
3.2. Patient ‘case study’ 
We follow a single virtual patient in detail through second and third 
modules of the framework for both the best and worst case trials. Note 
that the des-ist framework handles all virtual patients automatically, 
storing simulation data for each virtual patient in a separate directory. In 
Module II, the pre-stroke, stroke, and treatment events are run for the 
arterial blood flow and perfusion models. The blood flow and perfusion 
results for both the pre-stroke and stroke states are shown in Fig. 4. The 
treatment state will be either the same as the stroke state or revert to the 
pre-stroke case for the worst (unsuccessful recanalisation) and best 
(successful recanalisation) case trials respectively. From the change in 
perfusion between the three events, we can estimate the infarct volume 
at 24 h after treatment in both cases: successful recanalisation (best 
case) and unsuccessful recanalisation (worst case), with the tissue death 
model. The best and worst case infarct volumes (at 24 h) for this patient 
are 225 mL and 332 mL respectively. Fig. 5 shows the final (post- 
treatment) perfusion state and calculated infarct for the worst case 
scenario. Patient characteristics and outcomes are summarised in 
Table 6. 
Module III uses the infarct volume and patient clinical parameters to 
determine the functional outcomes of NIHSS and mRS. This patient had 
a predicted mRS of 1 and 2, and an NIHSS of 8 and 13, in the best and 
worst case scenarios respectively. 
3.3. Trial results 
Using the infarct and outcome results for each patient, Module IV 
aggregates the data and provides population level details. Results are 
again shown here for two trials: a best case trial (successful recanalisa-
tion after treatment), and a worst case trial (failed treatment with un-
successful recanalisation after treatment). 
The infarct results for the worst case proof of concept trial are shown 
in Fig. 6, split by clot location. As can be seen here, there is minimal 
variation between patients with the same infarct location and side. The 
use of the same brain mesh for all patients, and an impermeable clot, 
would explain why patients with the same side and location occlusion 
have very similar infarct volumes. This will be addressed in future 
versions of the framework. The difference between infarct on opposite 
sides of the brain is more significant. Asymmetries in the system, such as 
in the brain mesh and vascular network, would explain the difference 
between the results for the different sides. 
Fig. 7 shows the distributions for pre-stroke ability comparing 
functional outcomes for the worst and best case trials, using the modi-
fied Rankin Scale Score (mRS). These appear qualitatively reasonable, 
however these trials are a proof of concept and results should not yet be 
considered credible. It is not yet feasible to perform a validation of these 
results as the treatment models, as well as the cell death and perfusion 
models, are not fully implemented, and variation in estimated outcomes 
are not taken into account. Such a validation study is future work for the 
project, using the MR CLEAN trial data [25,53] and the data of the 
HERMES collaboration [54,55]. Additionally, uncertainties around pa-
tient outcomes will be included in future versions of the framework. 
Table 3 
Assumptions related to each model relevant to the event-based modelling 
approach.  
Model Assumptions 
Module II Events (changes to state) are instantaneous (seconds) in 
comparison to the time scale of the treatment (hours) 
Arterial blood 
flow 
New steady state (pre-stroke to clot, and clot to treatment) 
achieved on a time scale of heart beats (seconds) 
Perfusion New steady state (pre-stroke to clot, and clot to treatment) 
reached on a time scale of heart beats (seconds) 
Thrombolysis No significant change to clot properties during 
thrombolysis—only significant change is the final clot length 
and whether the clot dissolved or not. 
Thrombectomy No significant change to system except at end of procedure, 
when recanalisation occurs or not. 
Tissue death Only significant changes are when the clot occurs, and if and 
when recanalisation occurs  
Table 4 
Inclusion criteria for the trial. ER: emergency room. *Note, the 
onset to ER criteria replaces the MR CLEAN trial criteria of 6 h 
between onset to start of thrombectomy treatment.  
Characteristic Criteria 
Age >18 years 
NIHSS at ER ≥2 
Onset to ER* <6 h 
Systolic blood pressure <185 mmHg  
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4. Discussion 
There are many publications about the advantages and limitations of 
ISTs [11,12,56–61], and their potential applications and challenges 
continue to emerge. Some expected use cases for ISTs include: 1) aiding 
trial design by providing additional information; 2) drug rescue and 
detailed explorations of drug failures in phase III trials; 3) reducing time 
for trial in rare diseases as lower numbers of patients required in the real 
clinical setting; 4) ability to explore tails of distribution; 5) predicting 
best and worst outcomes for patients to evaluate potential benefits of 
treatment development; 6) refinement, reduction, and replacement of 
animal trials. Additional to these use cases, there are several other ad-
vantages to using ISTs concurrently with traditional trials: 1) multiple 
treatments options can be tested on the same virtual patient; 2) reducing 
the number of participants and duration, and hence cost, of traditional 
clinical trials; 3) ability to take measurements not possible in a clinical 
setting; 4) higher accuracy than animal trials [62]. 
The IST presented here is an event-based simulation where models 
are called sequentially. The models are stand-alone packages due to the 
containerisation provided by either Docker or Singularity. The frame-
work is designed to be expandable and modular. An event-handler ex-
ecutes the models and can easily be extended to include more events and 
models. 
In section 2.2 we detailed the applicability of the event-based 
approach for the application. We determined it to be appropriate for 
the all models, though both the tissue death and thrombolysis require 
time-driven models. In order to account for this, we integrate throm-
bolysis model over the relevant treatment time in the treatment event, 
and similarly the tissue death model is integrated across the entire 
simulation period, using the different perfusion states and timings, in the 
follow up event. The main limitation to this approach is the error 
introduced if thrombolysis is found to affect clot structure enough that 
blood flow conditions through the occluded vessel change significantly 
in the hours prior to the treatment event. If this is the case, it would be 
possible to add intermediate update events to reduce this error. 
Though event-based modelling is appropriate for the processes 
modelled here, the approximation of events as instantaneous is not al-
ways possible. In addition, models may need to be coupled in a more 
complex way than has been used here. For instance, two-way coupling 
between the arterial blood flow and tissue perfusion models is currently 
being developed to capture effects such as retro-grade flow and collat-
eral flow. It is well-established that the presence of collateral vessels (as 
indicated by the collateral score) has a significant impact on patients’ 
outcome [63]. A collateral circulation model has been proposed recently 
[64] which can be straightforwardly added to the 1D blood flow model. 
The individual models will otherwise be identical to the models used in 
this work. However, the boundary conditions of the models will be 
updated based on a coupling algorithm that captures the vasculature 
between the models. This will allow the capture of the collateral circu-
lation including variability between patients. 
In the IST presented here, coupled models would be added as a single 
black box. Models that are completely time-driven, and not suited to the 
instantaneous event assumption, could also theoretically be run within 
the framework using a single event, similarly to the approach used for 
tissue death and thrombolysis, or using multiple events allowing step-
wise change. 
One significant obstacle relevant to modelling stroke injury and 
treatment for large numbers of patients is the computational challenge 
related to modelling processes occurring on seconds over time periods of 
hours. Using the approach present here each patient, with three events, 
ran in 16 min on average. Statistical and surrogate modelling can be 
used to speed up the IST by replacing complex and computationally 
expensive models. For example, this will be implemented for the 
thrombectomy model, as a full FEA analysis for every patient is not 
currently computationally feasible. The requirement for a high detail 
model is also expected to be unnecessary given we are interested in 
population level outcomes for the trial. Hence speed is prioritised over 
per-patient detail provided the surrogate model is sufficiently validated 
to the level required for the trial’s credibility requirements. In certain 
scenarios, computational models are not available and statistical 
NIHSS at ER Systolic pressure (mm Hg)
Age (years) Duration onset to ER (min)
10 20 30 40 75 100 125 150 175


























Fig. 3. A selection of baseline parameters for the 
generated virtual population using Module I. Results 
are for 500 patients. Duration onset to ER de-
termines the timing of the events in the event-based 
model; systolic pressure and occluded segment are 
used for the models in Module II; and all these 
variables factor into the patient outcome in Module 
III. Occluded segments: middle cerebral artery sec-
tions M1 and M2, intracranial internal carotid artery 
(ICA), internal carotid artery terminus (ICA-T). 
NIHSS: National Institutes of Health Stroke Scale.   
Table 5 
Baseline (at ER) characteristics of the population.  
Characteristic Median (IQR) 
Age (years) 68.9 (60.9, 79.3) 
NIHSS at ER 15.4 (11.0, 19.1) 
Duration onset to ER (mins) 57.2 (34.7, 96.4) 
ASPECTS at ER 9 (7, 10) 
Sex (% Male) 55%  
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modelling is the only choice. 
Another major challenge for ISTs is the development of policy and 
procedures around proving credibility of the trial via validation, veri-
fication, and uncertainty quantification (VVUQ) practices [14]. 
Currently, the individual models within the trial are undergoing inde-
pendent validation activities, including the virtual population model, 
patient outcome model, and the physics-based models in Module II, 
using both clinical and in vitro testing [65,66]. However, the individual 
credibility of each individual models does not necessarily translate 
directly to the credibility of the trial. 
For the trial level verification, validation, and uncertainty quantifi-
cation (UQ) processes we will take guidance from the V&V40 standard 
from the ASME [67]. We do not yet include the treatment models 
required to perform a robust validation of the framework, and addi-
tionally the tissue death model is still under development. Consequently, 
the proof of concept trials shown in this paper are purely a demonstra-
tion of the framework and the methodologies and results should not be 
interpreted as validated nor representative of expected outcomes. Once 
the remainder of the models are included, it will be possible to validate 
the trial software against previous trial data from MR CLEAN Trial and 
Fig. 4. Transverse view of pressure distributions estimated by the 1D blood flow model (left) and perfusion model predictions (right) in the healthy baseline case 
(top) and in stroke state (bottom) for a virtual patient. 
Fig. 5. Transverse view of perfusion change (left) and the corresponding infarct (right) for a virtual patient in the worst case scenario. The estimated worst case 
infarct volume is 332 mL. 
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more detailed data from clinical practice included in the MR CLEAN 
Registry [24,25,53]. 
Preliminary trial level UQ analyses have been performed on the one 
way coupled arterial blood flow and perfusion models in Ref. [68]. In the 
future, a more extensive UQ analysis will be performed to understand 
the effect of the variability of parameters not measured in a clinical 
setting, and hence not included in the virtual population model. Addi-
tionally, trial outcomes will incorporate uncertainty around the pa-
tient’s functional outcome, which can be directly determined from the 
ordinal logistic model, allowing for a better understanding of the vari-
ation that can occur in patient outcomes given the limitations of the 
clinical information available, as in Ref. [31]. UQ activities will also 
consider the potential errors introduced when using lower computa-
tional versions of the models, such as the exclusion of collateral 
modelling. 
A key requirement for the validation activities is available, and 
shareable, high quality patient data and anatomies. Additionally, such 
data is needed to create virtual patients and their relevant parameters 
for the models. In order to minimise legal patient data issues for the trial 
itself, we use a virtual patient generation model to generate synthetic 
patients. However, these issues still remain for the validation activities. 
5. Conclusion 
We have presented a comprehensive framework, using an event- 
based modelling approach, for an in silico trial (IST), and applied it to 
acute ischemic stroke (AIS). The framework includes four modules for 
generating patients, modelling disease and treatment, determining 
functional outcome, and collating population level results. 
By using a statistical model for the patient generation, we are able to 
work around privacy limitations involved with data sharing. Predicting 
complex phenomena, such as infarct volume, requires linking together 
multiple models. In the second module, several physics-based models 
need to be combined in order to determine the brain injury for each 
patient. We use an event-based modelling approach where changes to 
the state of the brain are considered instantaneous, such as stroke and 
treatment. This approach aids in overcoming technical difficulties in 
combining models that use different mathematical approaches and time 
scales bridging three orders of magnitude. Additionally, surrogate 
models will be used for models with large computational requirements, 
such as the thrombectomy procedure, in order to make the model 
computationally feasible for large numbers of patients. 
The use of containerised environments aids in reproducibility of IST 
results. Additionally, using Docker or Singularity containers combined 
with a modular framework, we have built des-ist so that it is 
straightforward to add further models to the system. The two models for 
AIS treatment are still under development, and hence this paper presents 
two proof of concept trial comparing outcomes for successful and un-
successful recanalisation on the same virtual population cohort. The 
treatment models will be integrated into the trial in the future and will 
allow us to test the applicability of the instantaneous change assumption 
for the treatment event (Table 3). We will also then be able to investigate 
the impact of different aspects of treatment, such as number of throm-
bectomy passes and thrombolysis administration time, with respect to 
Table 6 
Patient characteristics and outcomes. Best case corresponds to successful 
recanalisation, and worst case is unsuccesful recanalisation (with no change to 
clot). Baseline is on presentation at the ER. MCA: Middle cerebral artery.  
Parameter Baseline Best case Worst case 
Duration onset to ER 23.2 min   
Duration onset to treatment 61.5 min   
ASPECTS at baseline 8   
NIHSS at baseline 9   
Clot location Right MCA   
Systolic blood pressure 157.4 mm.Hg   
Infarct volume at 24 h  225 mL 332 mL 
mRS  1 2 
NIHSS at 24 h  8 13  
M1 M2
ICA−T Intracranial ICA






















Fig. 6. Infarct volumes from the worst case (unsuccessful recanalisation) trial. L: left side, R: Right side. Infarct locations: middle cerebral artery sections M1 and M2, 
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0 1 2 3 4 5 6
Fig. 7. The modified Rankin Scale Score, determined from infarct volume and 
patient characteristics, for the baseline (at ER); and best (successful recanali-
sation) and worst (unsuccessful recanalisation) case scenario for each patient. 
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model sensitivities and also trial outcome. 
Many challenges still remain for ISTs. One significant being proving 
the credibility of the framework. We plan to undertake validation, 
verification, and uncertainty quantification on the trial [68], using MR 
CLEAN trial data and drawing on recommendations from the 
V&V40-2018 standard [67]. Being able to prove the credibility of the 
trial is critical for future approval of the software as a part of the R&D 
process for new drugs and treatments. 
Credit author statement 
Claire Miller: Investigation, Writing - Original Draft, Visualization. 
Raymond Padmos: Methodology, Writing - Original Draft, Visualization. 
Max van der Kolk: Software, Investigation, Writing - Review and Editing. 
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Appendix A Details of Module II models 
A.1 Arterial blood flow model 
A one-dimensional blood flow model is used to simulate blood flow and pressure during healthy and stroke scenarios. Blood flow is considered to 
be at steady state, i.e. variables are considered to be the average over the duration of a heart beat. Blood is modelled as an in-compressible fluid. The 







= Si, (B.1)  
with Gij, the conductance in m3 Pa− 1 s− 1 between nodes i and j, and Si a source term for node i. The conductance of a segment is given by G = πR4/
[2(ζ +2)μL], where R is the radius, L is the segment length, μ is the dynamic viscosity set to 3.5 mPa s, and ζ is a dimensionless constant related to the 
velocity profile, with two representing a parabolic profile, i.e. laminar flow, and nine representing a flatter profile used in this model [69]. The larger 




. Blood vessels 
are modelled as thin elastic tubes. A pressure-area relationship is used to model the elasticity of the vessel, given by 













, (B.2)  
where A is the cross-sectional area, A0 is the initial area, P is the pressure, P0 is a reference pressure set to the diastolic pressure, E is the Young’s 
modulus, h is the wall thickness and ν = 0.5 is the Poisson ratio of the vessel wall. 
The steady state approach is chosen for its simplicity. In addition, the time scale of interest, i.e. tissue infarction, is much longer than the cardiac 
cycle. Approximating arterial blood flow as steady state is therefore appropriate in this context. The steady state equations are derived from those 
commonly used in 1D blood flow modelling with the assumption that the velocity derivatives in time and space are zero. Validation of the entire model 
is still ongoing. The blood flow model itself is essentially the Poiseuille equation for fluid flow in a pipe, which has been used and validated extensively 
[71,72]. 
A.2 Perfusion model 
The perfusion model relies on a multi-compartment porous continuum representation of the microcirculation. This approach is becoming a popular 
choice both in heart [73–75] and brain perfusion modelling [36,66,76–82]. The corresponding governing equations are 
∇⋅(Ka∇pa) − βac(pa − pc) = 0; (B.3a)  
∇⋅(Kc∇pc) + βac(pa − pc) − βcv(pc − pv) = 0; (B.3b)  
∇⋅(Kv∇pv) + βcv(pc − pv) = 0, (B.3c)  
where pi and Ki are the Darcy pressure and the permeability tensor functions in the ith compartment. The subscripts i = a, c, and v symbolise the 
arteriole, capillary and venule compartments. Connection between the ith and jth compartments are established by the terms including the βij coupling 
coefficients. 
In the healthy baseline scenario, constant pressure is described as boundary condition on the cortical surface of the brain geometry [83,84] both in 
the arteriole and venule compartments. The arteriole boundary pressure is computed by the arterial blood flow model whereas the venule pressure is 
selected as the reference value and hence it drops out. In the stroke scenario, zero blood flux is enforced through the cortical surface corresponding to 
the occluded vessel. Boundary conditions on the remaining surfaces (including the ventricular boundaries in the arteriole and venule compartments, 
and every boundary of the capillary compartment) ensure zero blood flux (zero pressure gradient) in every case. 
It has been demonstrated that the permeability tensors can be replaced with single scalars representing the isotropic capillaries [85], and vessel 
bundles of penetrating arterioles and venules [36]. The governing equation set (B.2) is discretised using a tetrahedral brain mesh and solved 
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numerically using FEniCS [86,87], an open-source finite element library. Perfusion is defined as F = βac(pa − pc) according to Ref. [81]. Baseline model 
parameters are determined to match grey and white matter perfusion values corresponding to an average elderly patient so that virtual patients can be 
generated based on parameter perturbations [36]. Validation results so far indicate that the model predicts realistically blood flow rate through major 
cortical territories in healthy cases as well as infarcted regions in stroke cases [36,66]. Further validation and uncertainty quantification of the model 
is in progress based on comprehensive quantitative clinical imaging data. 
A.3 Tissue health model 
The tissue health model is a set of hypoxia-driven ordinary differential equations based on perfusion in each tetrahedral element of the brain mesh 
used for the perfusion computation. Due to the limited knowledge of white matter, the perfusion in white matter element is scaled to grey matter level 
based on the healthy perfusion ratio between the two. 
By implementing the Green’s function methods [88], oxygen transport and tissue oxygenation can be simulated under a certain perfusion in the 
physiologically representative human microvascular cubes [85]. With the criteria of hypoxia as PO2 < 10 mmHg [89], the tissue hypoxic fraction 
(fraction of hypoxic tissue in each cube) can be expressed as a function of perfusion. Here we assume that the relationship between hypoxia and 
perfusion is homogeneous because oxygen transport has been found to be independent of the variability of microvascular geometry and of length 
scales up to hundreds of microns [37]. The details of oxygen transport simulations can be found in our previous study [37]. 
The hypoxic fraction drives a modified 3-state cell death model [37,90]. In the modified 3-state model inspired by Ref. [91], hypoxia activates 
toxin release which furthers the transition of local cell compartments from alive to dead. There is also a toxin cleaning mechanism, which will 
dominate over toxin releasing and slow down further tissue damage, when the hypoxia is eased after perfusion restoration. With two thresholds of 
dead cell fraction for penumbra and core, the model has been tuned and validated against monkey data [92]. By coupling the cell death model with the 
perfusion model, core and penumbra volumes in a virtual patient brain at a certain time can be predicted easily. Further details of the cell death model 
development, validation, and application will be presented in a future study. 
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Georgios Tsivgoulis, Guillaume Turc, European Stroke Organisation (ESO) 
guidelines on intravenous thrombolysis for acute ischaemic stroke, page 
2396987321989865, European Stroke Journal (February 2021), https://doi.org/ 
10.1177/2396987321989865. ISSN 2396-9873. 
[19] Guillaume Turc, Pervinder Bhogal, Urs Fischer, Pooja Khatri, Kyriakos Lobotesis, 
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B.W.E.M. Roos, Wouter Schonewille, Henk A. Marquering, Charles B.L.M. Majoie, 
Thrombus migration paradox in patients with acute ischemic stroke, Stroke 50 (11) 
(November 2019) 3156–3163, https://doi.org/10.1161/ 
STROKEAHA.119.026107. ISSN 0039-2499, 1524-4628. 
[48] Wahbi K. El-Bouri, Andrew MacGowan, Tamás I. Józsa, Matthew J. Gounis, 
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der Lugt, Maria A. de Miquel, Geoffrey A. Donnan, Yvo B.W.E.M. Roos, 
Alain Bonafe, Reza Jahan, Hans-Christoph Diener, Lucie A. van den Berg, Elad 
C. Miller et al.                                                                                                                                                                                                                                   
Computers in Biology and Medicine 137 (2021) 104802
12
I. Levy, Olvert A. Berkhemer, Vitor M. Pereira, Jeremy Rempel, Mònica Millán, 
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